Cost-Effectiveness Analysis of Advanced Radiotherapy Techniques for Post-Mastectomy Breast Cancer Patients

Yibo Xie, Beibei Guo, Rui ZhangResearch 2020 · DOI

Introduction

Post-mastectomy radiotherapy (PMRT) is a cornerstone of treatment for high-risk breast cancer, significantly improving survival rates by reducing local recurrence. However, traditional radiation—the current Standard of Care (SOC)—can inadvertently damage adjacent healthy organs. This exposure often leads to "radiogenic" side effects, such as cardiac toxicity, lung cancer, or secondary cancers in the contralateral breast, which may manifest years after treatment.

While advanced technologies like Intensity-Modulated Radiotherapy (IMRT) and Intensity-Modulated Proton Therapy (IMPT) offer superior precision in sparing healthy tissue, they come with significantly higher initial costs. Previous economic evaluations have largely focused on comparing radiation to no radiation, often overlooking the long-term economic and quality-of-life impacts of side effects. This study addresses this gap by performing a comprehensive cost-effectiveness analysis of seven advanced PMRT techniques compared to the SOC.

Methods

The researchers employed a Markov model to simulate the 15-year clinical trajectory of a hypothetical cohort of 55-year-old women with Stage III breast cancer. In this model, patients transition between various health states—such as "No Evidence of Disease," "Local Recurrence," "Cardiac Toxicity," or "Death"—in one-year increments.

The study evaluated the SOC against seven advanced modalities:

  • Intensity-Modulated Radiotherapy (IMRT)
  • Three variants of Volumetric Modulated Arc Therapy (STD-VMAT, NC-VMAT, MA-VMAT)
  • Tomotherapy (TOMO)
  • Mixed Beam Therapy (MIXED)
  • Intensity-Modulated Proton Therapy (IMPT)

Primary outcomes were measured in Quality-Adjusted Life-Years (QALYs) and the Incremental Cost-Effectiveness Ratio (ICER). A unique aspect of this model was the integration of Normal Tissue Complication Probability (NTCP) and Lifetime Attributable Risk (LAR) models to estimate the specific risks of heart and lung damage associated with each radiation technique.

Data Sources and Validation

Clinical probabilities for tumor recurrence and metastasis were synthesized from established literature, including data from the Early Breast Cancer Trialists' Collaborative Group. Treatment costs were derived from local Medicare reimbursement charges. To ensure accuracy, the model’s survival predictions were validated against CancerMath, a widely recognized prognostic tool for breast cancer.

Results and Key Insights

The analysis revealed several critical findings regarding the economic viability of advanced radiotherapy:

The Impact of Cardiac Toxicity

One-way sensitivity analysis identified the probability of cardiac toxicity as the most influential factor in the model. Because heart damage is both life-threatening and costly to manage, techniques that minimize radiation dose to the heart possess a significant cost-effectiveness advantage.

Cost-Effectiveness Thresholds

In health economics, a treatment is typically considered cost-effective if it falls below a "willingness-to-pay" (WTP) threshold, often set at $100,000 per QALY gained. At this threshold, all seven advanced techniques were found to be more cost-effective than the SOC. However, at a more conservative threshold of $50,000/QALY, none of the advanced techniques were consistently more cost-effective than the SOC.

IMRT as the Optimal Choice

Fixed-beam IMRT emerged as the most cost-effective advanced option, with an ICER of $27,310 per QALY compared to SOC. It provides a meaningful reduction in radiation dose to the heart and contralateral breast without the prohibitive costs associated with proton therapy. At a $100,000/QALY WTP, IMRT demonstrated a 99.8% probability of being the most cost-effective choice.

The Proton Therapy Paradox

While IMPT (Proton Therapy) yielded the highest QALYs due to its exceptional precision, it also carried the highest ICER ($74,564 per QALY compared to SOC). Its high initial treatment cost—nearly triple that of SOC—makes it the least cost-effective option from a payer perspective under current pricing models.

Discussion and Conclusion

This study demonstrates that advanced PMRT techniques are generally cost-effective for breast cancer patients when considering a WTP threshold of $100,000 per QALY. IMRT, in particular, represents a "sweet spot" between clinical benefit and economic feasibility.

Limitations and Future Directions

The study assumes equal tumor control across all techniques. If ongoing clinical trials demonstrate that advanced modalities like IMPT provide superior local control, their cost-effectiveness profiles would likely improve. Furthermore, this analysis utilized a "payer perspective" based on Medicare costs; a "societal perspective" accounting for lost wages and caregiver burdens might further favor high-precision treatments.

Future research will explore the impact of age, as younger patients may derive even greater economic benefit from avoiding long-term side effects. Additionally, the researchers plan to investigate the cost-effectiveness of hypofractionated PMRT (shorter, higher-dose courses), which is becoming increasingly common in clinical practice.

Summary updated

Abstract

Abstract Background: Prior cost-effectiveness studies of post-mastectomy radiotherapy (PMRT) only compared conventional radiotherapy versus no radiotherapy and only considered tumor control. The goal of this study was to perform cost-effectiveness analyses of standard of care (SOC) and advanced PMRT techniques including intensity-modulated radiotherapy (IMRT), standard volumetric modulated arc therapy (STD-VMAT), non-coplanar VMAT (NC-VMAT), multiple arc VMAT (MA-VMAT), Tomotherapy (TOMO), mixed beam therapy (MIXED), and intensity-modulated proton therapy (IMPT).Methods: Using a Markov model, we estimated the cost-effectiveness of various techniques over 15 years. A cohort of women (55-year-old) was simulated in the model, and radiogenic side effects were considered. Transition probabilities, utilities, and costs for each health state were obtained from literature and Medicare data. Model outcomes include quality-adjusted life-years (QALYs) and incremental cost-effectiveness ratio (ICER), and SOC was used as the reference.Results: For the patient cohort, IMRT is the most cost-effective technique with an ICER value of 27,310 $/QALY, and IMPT has the highest ICER of 74,564 $/QALY. One-way analysis shows that the probability of cardiac toxicity has the most significant impact on the model outcomes. The probability sensitivity analyses show that all advanced PMRT techniques are more cost-effective than SOC at a willingness-to-pay (WTP) threshold of 100,000 $/QALY, while almost none of the advanced techniques is more cost-effective than SOC at a WTP threshold of $50,000/QALY.Conclusion: Advanced PMRT techniques are more cost-effective for breast cancer patients at a WTP threshold of 100,000 $/QALY, and IMRT might be the most cost-effective option for PMRT patients.
BibTeX
@inproceedings{xie2020cost,
  author = {Yibo Xie and Beibei Guo and Rui Zhang},
  title = {{Cost-Effectiveness Analysis of Advanced Radiotherapy Techniques for Post-Mastectomy Breast Cancer Patients}},
  booktitle = {Research},
  year = {2020},
  doi = {10.21203/rs.2.23226/v1},
}
Figure